Virologic Outcomes and ARV Switch Profiles 2 Years After National Rollout of Dolutegravir to Children Less Than 15 Years in Southern Mozambique.
Michelle M GillNicole HerreraRui GuilazeAbdul MussaNataniel DengoAmancio NhangaveJaciara MussáPatricia PerezNilesh BhattPublished in: The Pediatric infectious disease journal (2023)
Viral suppression rates of ≥80% with minor variations by backbone were achieved during the 2-year DTG rollout. However, there were multiple anchor drug switches for over one-third of children, which may be attributable in part to drug stockouts. Long-term pediatric HIV management will only be successful with immediate and sustainable access to optimized child-friendly drugs and formulations.
Keyphrases
- antiretroviral therapy
- hiv infected
- young adults
- hiv positive
- human immunodeficiency virus
- hiv aids
- hepatitis c virus
- hiv infected patients
- sars cov
- quality improvement
- hiv testing
- emergency department
- type diabetes
- insulin resistance
- men who have sex with men
- metabolic syndrome
- skeletal muscle
- south africa
- low cost
- glycemic control
- childhood cancer